Abstracts

Broadly Reactive Neutralizing Activity Within the First 6 Months of HIV-1 Infection

According to the present knowledge, a fraction of HIV-1 infected individuals are able to generate broadly reactive neutralizing activity (brNA) after 2-4 years of infection and, in very rare occasions, close to the first year post-seroconversion. However, brNA has not been described in acute/recent HIV-1 infection.  In this study, serum samples from 157 antiretroviral-naïve individuals…

Specific IgG Subclasses Induced in RV305, a Late Boost Vaccination of RV144 Subjects

While RV144 vaccine-induced IgG3 to HIV-1 Env variable loops 1 and 2 (V1V2) correlated with decreased risk of HIV-1 acquisition, the responses were not durable. We studied IgG subclasses (IgG1-IgG4) in HIV-uninfected RV144 volunteers who completed their primary vaccination series 6-8 years earlier and were randomized to receive booster vaccinations with either ALVAC-HIV/AIDSVAX B/E (Gr1),…

Optimizing Resource Allocation to Reduce HIV Incidence Across Sub-Saharan Africa

New prevention interventions offer substantial promise for capitalizing on previous progress against the HIV pandemic; but it has been unclear how these can be deployed jointly to best effect and this is complicated by geospatial heterogeneities in the epidemic and its drivers. We hypothesize that a strategy which confronts epidemic heterogeneity and considers available prevention…

New ARVs Could Represent More Than USD 3 Billion in Cost Savings Through 2025

Several new antiretrovirals (ARVs) are likely to be introduced in low-and middle-income countries (LMICs) by 2019 that represent a range of clinical and cost advantages to current products. These include tenofovir alafenamide fumarate (TAF), low dose efavirenz (EFV400), and dolutegravir (DTG). As programs evaluate adoption of these products, it is important that they understand the…